Menorrhagia:
Indications for: LYSTEDA
Cyclic heavy menstrual bleeding.
Adult Dosage:
Treat for up to 5 days during menses. Swallow whole. ≥18yrs: Normal renal function (serum creatinine ≤1.4mg/dL): 1300mg three times daily; Cr >1.4–2.8mg/dL: 1300mg twice daily; Cr >2.8–5.7mg/dL: 1300mg once daily; Cr >5.7mg/dL: 650mg once daily.
Children Dosage:
Premenarchal: not recommended.
LYSTEDA Contraindications:
Active thromboembolic (eg, DVT, PE, cerebral thrombosis). History or risk of thrombosis or thromboembolism (eg, retinal vein or artery occlusion; thrombogenic valvular disease, thrombogenic cardiac rhythm disease, hypercoagulopathy). Concomitant combination hormonal contraceptives.
LYSTEDA Warnings/Precautions:
Exclude endometrial pathology prior to initiation. Not for use in postmenopausal women. Discontinue immediately if retinal venous or arterial occlusion occurs. Subarachnoid hemorrhage (cerebral edema/infarction may occur). Acute promyelocytic leukemia treated with oral tretinoin (increased procoagulant effect). Renal impairment. Pregnancy. Nursing mothers.
LYSTEDA Classification:
Antifibrinolytic.
LYSTEDA Interactions:
See Contraindications: for hormonal contraceptives. Increased risk of thrombotic events with Factor IX complex concentrates, anti-inhibitor coagulant concentrates, oral tretinoin: use not recommended. Tissue plasminogen activators (tPAs) may decrease efficacy of both tranexamic acid and tPAs.
Adverse Reactions:
Headache, sinus/nasal symptoms, pain (back, abdomen, musculoskeletal, joint), muscle cramps, migraine, anemia, fatigue; visual/ocular events, severe allergic reaction, ligneous conjunctivitis.
Generic Drug Availability:
YES
How Supplied:
Tabs—30
